Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)
Capsule summary Long-term disease control is challenging for patients with psoriasis. Current topical treatment follows a reactive approach to disease relapse.Long-term proactive management with calcipotriene/betamethasone dipropionate foam twice-weekly was more efficacious versus vehicle foam for prolonging time to first relapse, increasing time in remission and reducing number of relapses.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie Holst M ørch, Kim A. Papp, Jean-Luc Perrot, Linda Stein Gold, Amrit Takhar, Diamant Thaçi, Richard B. Warren, Andreas Wollenberg Source Type: research